Understand the source comparison
TB-4 Research REM Sleep Considerations: Comparison
REM Latency Reduced 28–35% Reduced 40–45% Baseline Faster REM onset may enhance memory consolidation or confound stress recovery studies Total REM Duration Increased 15–22% Increased 20–28% Longer REM bouts improve emotional regulation but may mask cognitive d
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- REM Latency
- Reduced 28–35%
- Reduced 40–45%
- Baseline
- Faster REM onset may enhance memory consolidation or confound stress recovery studies
- Total REM Duration
- Increased 15–22%
- Increased 20–28%
- Longer REM bouts improve emotional regulation but may mask cognitive deficits in impaired models
- Slow-Wave Sleep
- No significant change
- Physical recovery pathways (GH secretion, tissue repair) remain unaffected
- GABA-A Receptor Affinity
- Increased 18–25% (α5/δ subunits)
- Increased 30–38%
- Receptor modulation is dose-dependent and subunit-specific—no sedation or tolerance observed
- Circadian Disruption Risk
- Minimal if dosed AM
- Moderate if dosed PM
- None
- Late-day dosing risks phase-shifting REM cycles; morning dosing avoids this
- The data underscores a key principle: TB-4's REM effects are predictable and dose-dependent, but they require active management in study design. For protocols where sleep is a secondary outcome, standard tissue-repair doses (2–5mg twice weekly in humans) likely produce mild REM modulation without clinical significance. For neurological or behavioural studies, polysomnographic controls and timing adjustments become non-negotiable.